CASI Pharmaceuticals (CASI) Sees Large Volume Increase

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) saw unusually-strong trading volume on Friday . Approximately 1,616,445 shares traded hands during trading, an increase of 550% from the previous session’s volume of 248,862 shares.The stock last traded at $3.63 and had previously closed at $3.07.

A number of analysts recently issued reports on CASI shares. ValuEngine raised shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 15th. Maxim Group set a $4.00 price target on shares of CASI Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 14th. Finally, HC Wainwright reissued a “buy” rating and set a $2.00 price target on shares of CASI Pharmaceuticals in a report on Friday, September 8th.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.01. analysts anticipate that CASI Pharmaceuticals, Inc. will post -0.15 EPS for the current fiscal year.

In related news, Director Wei-Wu He acquired 207,502 shares of CASI Pharmaceuticals stock in a transaction on Tuesday, September 19th. The stock was bought at an average cost of $1.75 per share, for a total transaction of $363,128.50. Following the completion of the transaction, the director now owns 513,525 shares of the company’s stock, valued at approximately $898,668.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have acquired 996,329 shares of company stock valued at $1,647,138 over the last 90 days. 24.52% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

What are top analysts saying about CASI Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CASI Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit